2024 Ophthalmic Revenue Roundup for Alcon, Glaukos, Tarsus, and RxSight

Alcon Reports 2024 Net Sales of $9.8 Billion

Alcon reported Feb. 25 that its full year 2024 net sales totaled $9.8 billion, a 5 percent increase (+6 percent cc) over $9.4 billion in 2023.

Q4-2024 sales were $2.5 billion, a 6 percent increase (+6 percent cc) over $2.3 billion in Q4-2023.

David J. Endicott, Alcon’s chief executive officer, attributed growth in 2024 to the company’s focus on innovation and operational excellence.

Surgical net sales (for implantables, consumables, and equipment/other) in 2024 were $5.5 billion, a 4 percent increase (5 percent cc) over $5.3 billion in 2023.

Q4-2024 surgical net sales were $1.42 billion, a 5 percent increase (+5 percent cc) over $1.35 billion in Q4-2023.

The company said implantables’ Q4-2024 net sales of $456 million (up 4 percent, +2 percent cc) reflected demand for advanced technology intraocular lenses in international markets, partially offset by slower market conditions and competitive pressures in the US.

Consumables’ Q4-2024 net sales of $738 million (up 7 percent, +7 percent cc) were driven by vitreoretinal and cataract consumables, including price increases.

Equipment/other net sales in Q4-2024 of $229 million (up 1 percent, +2 percent cc) were driven by strong demand for equipment in international markets.

Switzerland-registered, Texas-based Alcon provided full year 2025 guidance of $10.2 billion to $10.4 billion, an increase of 6 to 8 percent over 2024.

Glaukos Posts 2024 Net Sales of $383.5 Million

Glaukos, of Aliso Viejo, California, reported Feb. 20 that its 2024 net sales were $383.5 million, a record and a 22 percent increase over $314.7 million in 2023.

The 2024 total consisted of glaucoma net sales of $303.3 million ($199.6 million in the US and $103.7 million outside the US) and corneal health net revenue of $80.2 million, up 3 percent over 2023. Photrexa sales in the US were $68.6 million, up 4 percent over 2023.

The company said 2024 was a successful year of global execution of key commercial and development plans, leaving Glaukos well positioned in 2025 and beyond.

Q4-2024 net sales were $105.5 million, a 28 percent increase over $82.4 million in Q4-2023.

The Q4-2024 total included glaucoma net sales of $84.1 million ($56.3 million in the US and $27.9 million outside the US), a 39 percent increase over $60.6 million in Q4-2023. Cornea health net sales were $21.4 million, a 2 percent decline from $21.8 million in Q4-2023. Glaukos said Q4-2024 results reflected the impact to Photrexa from the company’s entry into the Medicaid Drug Rebate Program (MDRP). 

Glaukos said it expects 2025 net sales to be in the range of $475 million to $485 million.

Glaukos noted that it had announced in Q4-2024 plans to build an expansive research, development, and manufacturing facility in Huntsville, Alabama, to augment its current infrastructure and support future expansion plans.

Tarsus Generates 2024 Net Product Revenue of $180.1 Million from Sales of Xdemvy

Tarsus Pharmaceuticals, of Irvine, California, reported 2024 net product revenue for Xdemvy of $180.1 million, compared with $14.7 million for about four months of sales in 2023.

Xdemvy was approved for Demodex blepharitis by the US FDA on July 24, 2023, and was available for prescription in the US by the end of August 2023.

Q4-2024 Xdemvy revenue was $66.4 million, compared with $13.1 million in Q4-2023.

The company said it dispensed more than 58,500 bottles to patients in Q4-2024 and 163 thousand bottles in full-year 2024.

Tarsus said factors driving growth in 2024 included expansion of its sales force in Q3-2024; broad commercial, Medicare, and Medicaid reimbursement; and activation of an action-oriented direct-to-consumer campaign on streaming platforms in Q4-2024.

RxSight Reports 2024 Revenue of $139.9 Million

RxSight reported Feb. 25 that its 2024 revenue was $139.9 million, a 57 percent increase over $89.1 million in 2023.

The Aliso Viejo, California, company said the increase was due to a 15 percent increase in unit sales of Light Delivery Devices (305 sold in 2024), expanding the installed base to 971 systems, and a 79 percent increase in sales of Light Adjustable Lenses (98,055 sold in 2024) over 2023.

Q4-2024 revenue was $40.2 million, a 41 percent increase over $28.6 million in Q4-2023.

Ron Kurtz, MD, chief executive officer and president of RxSight, said in a statement: “The progress we’ve made over the past year has strengthened our conviction that adjustability has the potential to transform the premium cataract market, and that we are still in the early stages of realizing this vision.”

RxSight projects 2025 full year revenue of $185.0 million to $197.0 million, representing growth of 32 to 41 percent over 2024.